Seminars in Arthritis and Rheumatism

Papers
(The H4-Index of Seminars in Arthritis and Rheumatism is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Corrigendum to “Relapses in giant cell arteritis treated with tocilizumab. Retrospective multicenter study of 407 patients in clinical practice” [Seminars in Arthritis and Rheumatism 71 (2025) 152640]106
Interstitial lung disease in patients with antineutrophil cytoplasmic antibody-associated vasculitis: chest CT patterns and correlation with survival82
Risk prediction models for incident systemic lupus erythematosus among women in the Nurses’ health study cohorts using genetics, family history, and lifestyle and environmental factors80
mRNA vaccines in the rheumatologist's future73
Combotherapies in immune-mediated inflammatory diseases: A study using the Clinical Data Warehouse from Paris Hospitals’ Public Assistance73
OMERACT validation of a deep learning algorithm for automated absolute quantification of knee joint effusion versus manual semi-quantitative assessment71
Hip and pelvis region MRI reference image atlas for scoring inflammation in peripheral joints and entheses according to the OMERACT-MRI WIPE scoring system in patients with spondyloarthritis64
Hydroxyquinone use does not increase the risk of venous thromboembolism in rheumatoid arthritis patients—Real-world evidence from a population-based cohort study59
Response letter to the editor58
OMERACT Core outcome measurement set for shared decision making in rheumatic and musculoskeletal conditions: a scoping review to identify candidate instruments52
Letter to the editor regarding Outcomes in patients with rheumatoid versus osteoarthritis for total hip arthroplasty: A meta-analysis and systematic review43
Immunotherapy in cancer42
Update on IgG4-related periaortitis/retroperitoneal fibrosis and periarteritis -recent clinical, diagnostic and therapeutic advances42
The Autoantibody response in rheumatoid arthritis; what makes it unique?41
Expanding the role of mycophenolic acid in pediatric lupus nephritis: A holistic approach to extrarenal findings, side effects, and long-term outcomes38
Response to the correspondence by Xu et al. regarding "Toward a more actionable RA-ILD risk model"37
Factors predictive of severe thrombocytopenia and its impact on poor outcomes in Latin American patients with systemic lupus erythematosus: Data from a multiethnic Latin American cohort36
Is mixed connective tissue disease (MCTD) a subtype of systemic sclerosis?36
Risk of malignancy in patients with systemic lupus erythematosus: Systematic review and meta-analysis35
Hidden in plain sight: Is there a crucial role for enthesitis assessment in the treatment and monitoring of axial spondyloarthritis?34
Survival of adults with rheumatoid arthritis associated interstitial lung disease - A systematic review and meta-analysis33
Immunogenicity of Rituximab biosimilar GP2013 in chronic inflammatory rheumatic disorders in daily clinical practice32
Quantification of coronary artery calcification in systemic sclerosis using visual ordinal and deep learning scoring: Association with systemic sclerosis clinical features31
Looking at Fibromyalgia differently – the meaning and consequences of fibromyalgia as a dimensional disorder30
Refining RA-ILD screening: Diagnostic limitations and the emerging role of lung ultrasound30
Performance of cut-offs of the ASAS Health Index to discriminate between treatment groups in patients with axial spondyloarthritis in the TICOSPA trial30
Disease characteristics, co-morbidities and treatment response in a contemporary axial spondyloarthritis cohort: Analysis of 717 patients from the Greek AxSpA registry29
A clue for subclinical CNO in adolescents with acne conglobata and hidradenitis suppurativa: Persistan acute phase rectans elevation29
Sodium-glucose cotransporter 2 (SGLT2) inhibition and autoimmunity28
Using patient reported outcomes measurement information system (PROMIS®) measures in rheumatoid arthritis clinical care, research, and trials28
0.16589593887329